Rejuva

About Fractyl Health

Fractyl Health is on a mission to break the pattern of chronic drug therapy for obesity and type 2 diabetes by developing durable, disease-modifying treatments. The company's two core platforms target key metabolic organs: Revita addresses duodenal dysfunction via an outpatient endoscopic procedure, while Rejuva is a novel AAV gene therapy targeting pancreatic islet cells. Fractyl is publicly traded (NASDAQ: GUTS) and is advancing its pivotal REMAIN-1 study for Revita, positioning it at the intersection of the massive obesity and diabetes markets with a focus on long-term solutions beyond chronic pharmacotherapy.

Therapeutic Areas